If you or a loved one has been taking Reglan (metoclopramide) and noticed unusual facial or body movements, you may be observing early signs of tardive dyskinesia. Decades of pharmacovigilance have established that prolonged use of this medication can lead to this often-irreversible movement disorder. This page covers the key symptoms to watch for and what the medical literature says about monitoring and risk factors.
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning also notes that Reglan is contraindicated in patients with a history of TD, and that the medication should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The prescribing information describes TD as a syndrome of potentially irreversible and disfiguring movements, and notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation can include grimacing, lip smacking, tongue protrusion, and rapid eye blinking, among other movements. Diagnosis is typically based on clinical examination and history of exposure to a dopamine-blocking agent like metoclopramide.
The mechanistic pathway linking Reglan to TD involves its action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the striatum is believed to lead to upregulation of these receptors and subsequent supersensitivity, which manifests as involuntary movements. The risk of developing TD is directly related to the duration of metoclopramide treatment and the total cumulative dose received (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with gastroesophageal reflux, the maximum recommended treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the labeling advises avoiding treatment longer than 12 weeks, and if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these guidelines, many patients have been prescribed Reglan for extended periods, increasing their risk. The adequacy of warnings regarding Reglan and TD is a critical issue. The boxed warning is prominently placed in the prescribing information, but questions arise about whether prescribers and patients were sufficiently informed about the risk, especially given that TD can develop after relatively short-term use and may persist even after discontinuation. The labeling states that Reglan should be immediately discontinued if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be masked by the medication itself, early detection may be challenging.
For affected patients in Ohio, attorney-related considerations involve the statute of limitations for filing a claim. In Ohio, personal injury claims generally must be filed within two years of the date the injury was discovered or should have been discovered. For TD, this timeline can be complex because symptoms may develop gradually and may not be immediately linked to Reglan use. The statute of limitations may begin when the patient knew or reasonably should have known that their movements were caused by Reglan. Given that TD can appear months or even years after starting the medication, the discovery date is a key factor. Patients who were prescribed Reglan for longer than the recommended 12-week period may have stronger claims, as the labeling explicitly warns against extended use without monitoring. The timeline between exposure and documented harm varies. Some patients develop TD after only a few months of treatment, while others may not show symptoms until after years of use. The labeling emphasizes that the risk increases with duration and cumulative dose, meaning that patients who took Reglan for extended periods are at higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once TD is diagnosed, the condition is often permanent, and treatment options are limited. Legal claims may focus on failure to warn, inadequate monitoring, or prescribing beyond recommended durations. In summary, Reglan carries a well-documented risk of tardive dyskinesia, with the FDA requiring a boxed warning. The risk is dose- and duration-dependent, and the medication is contraindicated in patients with a history of TD. For Ohio patients, the statute of limitations for filing a claim is typically two years from discovery of the injury. Given the potential for delayed onset and the masking of symptoms, patients should seek legal counsel promptly if they suspect Reglan-related TD.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered. For tardive dyskinesia caused by Reglan, this means the clock starts when the patient knew or reasonably should have known that their involuntary movements were linked to Reglan use. Because symptoms can develop gradually, it is important to consult an attorney promptly.
Reglan (metoclopramide) is a dopamine receptor antagonist. Chronic blockade of dopamine D2 receptors in the brain can lead to receptor upregulation and supersensitivity, resulting in involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses, as noted in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Tardive dyskinesia involves involuntary, repetitive movements such as grimacing, lip smacking, tongue protrusion, rapid eye blinking, and movements of the trunk or extremities. These movements can be disfiguring and are often irreversible. The condition may be masked by the medication itself, delaying diagnosis.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.